Trials / Completed
CompletedNCT02939872
Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events
Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events: BVS-LATE Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 238 (actual)
- Sponsor
- Seung-Jung Park · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate optimal duration of antiplatelet therapy after Bioresorbable Vascular Scaffold implantation to reduce late coronary arterial thrombotic events.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | aspirin and clopidogrel | at the discretion of investigator |
| DRUG | Clopidogrel only | at the discretion of investigator |
Timeline
- Start date
- 2017-03-09
- Primary completion
- 2021-05-09
- Completion
- 2024-06-03
- First posted
- 2016-10-20
- Last updated
- 2024-06-25
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02939872. Inclusion in this directory is not an endorsement.